Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline.
No Thumbnail Available
All Authors
Chaganti, S.
Fox, CP.
Maybury, BD.
Burton, C.
Barrington, SF.
Illidge, T.
Kalakonda, N.
Eyre, TA.
McKay, P.
Kuhnl, A.
LTHT Author
Burton, Cathy
LTHT Department
Oncology
Haematology
Haematology
Non Medic
Publication Date
2025
Item Type
Journal Article
Practice Guideline
Practice Guideline
Language
Subject
Subject Headings
Abstract
Time to progression is the strongest predictor of outcome in relapsed diffuse large B-cell lymphoma. Second-line treatment with chimeric antigen receptor (CAR) T-cell therapy is recommended for patients with progression within 12 months of first-line chemoimmunotherapy. In patients with late relapse, platinum-based chemotherapy followed by high-dose chemotherapy with autologous stem cell rescue is recommended. In second relapse, CAR T-cell or CD3xCD20 bispecific antibody therapy is recommended in eligible patients. Other treatment options are available for less fit patients. Specific recommendations are made on diagnostic immunohistochemistry, bendamustine use and bridging to CAR T-cell therapy.
Journal
British Journal of Haematology